|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.00 EUR | +0.51% |
|
-0.89% | -9.32% |
| 12-05 | SANOFI : Buy rating from Bernstein | ZD |
| 12-05 | Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns | RE |
| Capitalization | 103B 120B 96.89B 90.31B 167B 10,829B 181B 1,133B 438B 5,114B 452B 442B 18,700B | P/E ratio 2025 * |
12.4x | P/E ratio 2026 * | 12.4x |
|---|---|---|---|---|---|
| Enterprise value | 116B 135B 108B 101B 187B 12,120B 203B 1,268B 490B 5,724B 505B 495B 20,929B | EV / Sales 2025 * |
2.66x | EV / Sales 2026 * | 2.44x |
| Free-Float |
87.31% | Yield 2025 * |
4.89% | Yield 2026 * | 5.05% |
Last Transcript: Sanofi
| 1 day | +0.51% | ||
| 1 week | -0.89% | ||
| Current month | -0.89% | ||
| 1 month | -0.71% | ||
| 3 months | +6.92% | ||
| 6 months | -3.86% | ||
| Current year | -9.32% |
| 1 week | 84.3 |  | 87.25 |
| 1 month | 84.3 | | 90.79 |
| Current year | 76.15 | | 110.88 |
| 1 year | 76.15 | | 110.88 |
| 3 years | 76.15 | | 110.88 |
| 5 years | 74.92 | | 110.88 |
| 10 years | 62.5 | | 110.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 58 | 31/08/2019 |
| Director of Finance/CFO | 63 | 31/03/2024 | |
Madeleine Roach
COO | Chief Operating Officer | 41 | 30/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 72 | 30/04/2014 |
| Director/Board Member | 60 | 29/04/2019 | |
Paul Hudson
BRD | Director/Board Member | 58 | 29/10/2019 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.66% | 150 M€ | +17.82% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.51% | -0.89% | -7.79% | -0.46% | 120B | |
| -0.41% | -6.06% | +22.21% | +174.14% | 905B | |
| -0.27% | -2.41% | +35.24% | +14.67% | 487B | |
| -1.15% | -0.71% | +28.32% | +38.09% | 400B | |
| +0.26% | +1.14% | +20.97% | +1.87% | 330B | |
| +0.58% | -2.73% | +27.58% | +21.90% | 281B | |
| +0.19% | +2.49% | +19.23% | +25.56% | 255B | |
| -1.16% | -4.87% | -3.27% | -8.45% | 248B | |
| +1.24% | -2.33% | -60.59% | -30.82% | 214B | |
| -3.02% | -4.51% | +21.03% | +16.45% | 178B | |
| Average | -0.32% | -2.09% | +10.29% | +25.29% | 341.68B | |
| Weighted average by Cap. | -0.34% | -2.72% | +16.72% | +54.83% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 43.48B 50.58B 40.73B 37.96B 70.12B 4,552B 76.27B 476B 184B 2,150B 190B 186B 7,861B | 46.51B 54.1B 43.57B 40.61B 75B 4,869B 81.58B 510B 197B 2,300B 203B 199B 8,409B |
| Net income | 8.33B 9.69B 7.81B 7.28B 13.44B 872B 14.62B 91.3B 35.25B 412B 36.38B 35.61B 1,507B | 8.32B 9.68B 7.79B 7.26B 13.42B 871B 14.59B 91.16B 35.2B 411B 36.32B 35.55B 1,504B |
| Net Debt | 12.33B 14.34B 11.55B 10.76B 19.88B 1,291B 21.63B 135B 52.16B 610B 53.83B 52.68B 2,229B | 9.91B 11.53B 9.28B 8.65B 15.98B 1,037B 17.38B 109B 41.92B 490B 43.26B 42.34B 1,791B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 85.00 € | +0.51% | 2,004,635 |
| 04/12/25 | 84.57 € | -1.25% | 2,217,125 |
| 03/12/25 | 85.64 € | -0.59% | 1,447,788 |
| 02/12/25 | 86.15 € | -0.51% | 1,205,255 |
| 01/12/25 | 86.59 € | +0.97% | 2,021,650 |
Real-time Euronext Paris, December 05, 2025 at 04:55 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SAN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition